Answers from Investor Relations1. Why does the share price continue to drop with every good news release? - We think it is more of a reflection of market volatility rather than a direct correlation to VIVO news releases. VIVO tends to trade in a similar pattern to its peers 2. How much lower is Vivo's share price going to drop? - Unfortunately that is not something anyone can predict or control. We are focused on controlling what we can control and that is executing against our operations and growth plan. Specifically, increasing production capacity to achieve economies of scale and expanding our product line and in both regards we have been successful. 3. Is there something going on behind the scenes for me to have concerns that Vivo might go bankrupt? - No from a balance sheet perspective, VIVO is well-positioned, with $68 million in cash and non-equity investments as at the end of Q1 2019. 4. Is the stock being manipulated for a possible hostile takeover or buyout? - We do not believe the shares are being manipulated. 5. Does Vivo's future look any brighter than this? - Yes in addition to operating against its business plan (see answer 2 for more details in that regard) the company is focused on 4 strategic priorities as follows: 1. 1. Expanding capacity and increasing production capability InQ1 2019, VIVO doubled its annual production capacity at both its Canna Farms facility in Hope, B.C., and its Vanluven facility in Napanee, Ontario, and commenced construction on Phase 5 of the Canna Farms facility. VIVO has also acquired additional properties to further expand 2 acres in Hope, B.C., adjacent to the Canna Farms facility, and 16 acres zoned for cannabis cultivation within 15 minutes of the Canna Farms facility. This is in addition to the 65 acres already owned by the Company minutes from the Vanluven facility in Napanee, Ontario, where VIVO is completing the construction of its new Kimmett facility. 2. 2. Leadership in the Canadian medical market VIVO has continued to build upon the Canna Farms medical cannabis platform (https://www.cannafarms.ca),where patients can access the widest selection of cannabis strains, and where cannabis cultivators can enter the medical marketplace, make a fair return on their quality products, and avoid having to implement the processes necessary to navigate the complexities of the medical cannabis fulfillment space. The platform now provides patients access to products cultivated by four separate licensed producers. Harvest Medicines business continues to expand, with the roll out of the HMED Connect telemedicine platform bringing medical cannabis information to the wide patient population that can benefit from being educated about the applications and proper use of medical cannabis. 3. 3. Innovation and product development VIVOs GMP-designed Vanluven facility is conducting ongoing research related to the development of optimized indoor, seasonal greenhouse and outdoor grown cannabis cultivars, as well as developing as a center of excellence for extraction via multiple methodologies, and for formulation expertise in the development of cannabis infused edibles and beverages. VIVO expects to receive Health Canada approval of its supercritical CO2 extraction facility in Q2 2019 and additional extraction capacity is expected to come on-line in Q3 2019. The seasonal greenhouses, which represent Phase I of VIVOs innovative new Kimmett facility, are currently undergoing a pre-licensing review by Health Canada and, pending approval, are expected to produce up to 3,000 kilograms of cannabis for extraction in 2019. The Company has multiple products in development in anticipation of the opening of the edibles, concentrates and beverages market in late 2019, as well as multiple cannabis-based medical products in development. 4. 4. International market growth VIVO continues to focus on targeted international expansion activities and intends to expand into select markets in which medical cannabis can be legally prescribed, leveraging the strong pharmaceutical background of its leadership team, its experience operating the Harvest Medicine clinics, and its work with patients that have benefited from medical cannabis, to increase its global footprint as a leader in the medical cannabis sector. One of the Companys partners is currently propagating VIVO cultivars in a GMP facility in Europe. The Companys Australian strategy is also developing along multiple lines in step with the expansion of the Australian medical market. VIVO has shipped product to Australia from both its Canna Farms and Vanluven facilities as of Q1 2019.